首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives
【24h】

Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives

机译:协同药物组合的纳米药物用于癌症治疗-策略和观点

获取原文
获取原文并翻译 | 示例
       

摘要

Nanomedicine of synergistic drug combinations has shown increasing significance in cancer therapy due to its promise in providing superior therapeutic benefits to the current drug combination therapy used in clinical practice. In this article, we will examine the rationale, principles, and advantages of applying nanocarriers to improve anticancer drug combination therapy, review the use of nanocarriers for delivery of a variety of combinations of different classes of anticancer agents including small molecule drugs and biologics, and discuss the challenges and future perspectives of the nanocarrier-based combination therapy. The goal of this review is to provide better understanding of this increasingly important new paradigm of cancer treatment and key considerations for rational design of nanomedicine of synergistic drug combinations for cancer therapy. (C) 2016 Elsevier B.V. All rights reserved.
机译:协同药物组合的纳米药物在癌症治疗中已显示出越来越重要的意义,这是由于其有望为临床实践中使用的当前药物联合疗法提供优越的治疗益处。在本文中,我们将研究应用纳米载体改善抗癌药物联合治疗的原理,原理和优势,回顾纳米载体用于递送各种不同类型的抗癌药物(包括小分子药物和生物制剂)的多种组合的用途,以及讨论基于纳米载体的联合疗法的挑战和未来前景。这篇综述的目的是提供对癌症治疗这一日益重要的新范例的更好理解,以及对用于癌症治疗的协同药物组合的纳米药物进行合理设计的关键考虑因素。 (C)2016 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号